Sign Up
Ready to replace complexity with clarity?
Answer your real world compliance questions (limited time) and save thousands in legal fees and avoided fines.
Automate Compliance TodayUS states A to Z: marijuana, THCA, delta-8, delta-9, delta-10, HHC
State-by-state mapMost read countries: marijuana, CBD and hemp status
All countries on the globeSubstances: status in every state for each one
Compare all substancesFederal hemp redefinition: P.L. 119-103, div. B, sec. 2019
Nov 12, 2026
Applies only to cannabinoids the plant cannot naturally produce.
Dec 11, 2026
The total-THC test, the 0.4 mg per container cap and the exclusion of converted cannabinoids start.
Latest regulatory actions, updated daily
All regulatory actionsHeadlines and the first four sentences are free. Full write-ups, impact reasoning and the archive are for members.
Member · $99/mo
Every rule change, the day it is made.
The price will rise. Join now and $99 a month stays your rate for life.
Become a memberOr read free: every action opens 30 days after it is published. Sign in with email
By topic
Licensing and permitsPackaging and labelingLab testing and QARetail complianceAdvertising and marketingBanking and paymentsTaxesShipping and logisticsTravel and transportLitigationSOPsFor your role
Regulators and agenciesBrands and operatorsRetailers and smoke shopsCultivatorsProcessorsLawyers and complianceInvestorsConsumers and travelersThe Regulator Brief · newsletter
Every rule change that matters, every Monday.
Free: the Monday brief, and every action 30 days after it is published.
Members: the paid weekly, daily alerts and every write-up.
Read by regulators, operators, lawyers and founders.
Cannabis lawyers
Licensed by state. Listings are not endorsements.
By state
Software and services
Compared by fit, never ranked.
Categories
For companies and firms
Be the listing operators and regulators find.
Software and services
Verified, $49/mo: domain-verified badge, your website link, a quote.
Featured, from $399/mo: labeled Featured in your category, monthly release notes.
Lawyers and firms
Claimed, $75/yr: Claimed badge and your firm's website link.
Featured, $199/mo: labeled Featured on your profile.
Claim your companyClaim a lawyer listingPlacements, flat monthly fee
State and country page sponsorshipsExclusive slot on a legality page and its postsRegulator Brief sponsorshipPresenting sponsor or mid-issue banner, free editionMember brief sponsor slotThe paid weekly, read by members onlyFeatured directory placementLabeled Featured in a software categoryCategory sponsorshipOwn one directory category across the sitePaid guest postsLabeled Paid guest post, sponsored linksWrite and partner
Pitch a paid guest postRead guest postsBecome an affiliateSend a tip or correctionContact the teamWho reads it
Regulators at federal, state and county agencies, plus the operators, lawyers and founders they regulate.
Get the media kitSee open placementsSubstances
US states, map and A to ZCountriesFederal hemp 2026: Nov 12 and Dec 11Compound index, every stateTravelling with cannabis or hempMembers get the daily alert email and every full write-up the morning it is published. Every action is free to read 30 days later.
For your role
All news and analysisGuidesAnalysisFAQsTemplates and SOPsCourt filing recapsNews by state and countrySoftware and services: Verified $49/mo, Featured from $399/mo. Lawyers and firms: Claimed $75/yr, Featured $199/mo. Listings are not endorsements.
Regulatory journalism, not legal advice. How we report

Colombia’s medical cannabis framework has existed for years, but patient access has largely centered on oils, extracts, and a limited set of finished products—often through specialized channels rather than everyday retail pharmacy workflows. In late July 2025, the national government published a draft decree that would explicitly authorize pharmacies (droguerías) to dispense medical cannabis flower when supported by a physician prescription, tightening rules for dispensing, patient verification, and marketing.
This proposal builds on Decree 811 of 2021, which already modernized several aspects of Colombia’s medicinal-use rules, including pathways that supported broader product forms and domestic distribution. The 2025 draft decree is best understood as an operational “last-mile” measure: it is aimed at normalizing access inside Colombia by using the existing pharmacy network, while still treating flower as a controlled, prescription-only item.
This article summarizes what the draft decree signals for Colombia medical cannabis pharmacies 2025: expected dispensing rules, likely prescription and patient-record requirements, INVIMA’s role, advertising/display restrictions, and how producers—especially those built around export-only models—should prepare for a domestic pharmacy rollout.
Important: This is informational only and not legal advice. Draft regulations can change before final publication.
Decree 811/2021 is widely referenced as the foundation for Colombia’s modern medical cannabis regulations, including recognition of additional product formats and the alignment of different authorities’ roles (licensing, health oversight, and controlled-substance handling). The July 2025 draft decree does not replace that system; it appears designed to clarify pharmacy dispensing as a standard channel for flower, and to define guardrails so that dispensing looks and behaves like other controlled prescription medicines.
For businesses, the practical takeaway is that the draft decree is likely to:
If you need the current baseline text for Colombia’s medical framework, start with official sources and consolidated references:
From a policy perspective, the July 2025 proposal targets several persistent issues:
Even when cultivation and manufacturing capacity exists, domestic access can lag if products are concentrated in non-pharmacy channels or in forms that patients do not prefer. The draft proposes a clear route for prescription flower to be dispensed through pharmacies, which could reduce friction for patients and prescribers.
Regulators typically view flower as a higher diversion risk and a higher “misuse optics” risk than oils/capsules, even when medically prescribed. The draft’s emphasis on pharmacist controls and identity checks aligns with that risk profile.
A major commercial implication is that a pharmacy channel would require:
The draft decree is focused on dispensing, not rewriting upstream licensing. That means core licensing still stems from Colombia’s existing medical regime (cultivation, manufacturing, and related authorizations).
What may change in practice is who becomes commercially relevant:
Business takeaway: Even if your licensing is already in place, pharmacy rollout can create “secondary compliance”—contracts, SOPs, training, returns/destruction procedures, and audit readiness.
A central question for Colombia medical cannabis pharmacies 2025 is how strict prescribing will be and what must appear on the prescription. While the final decree will control, the draft’s direction suggests a model similar to other controlled prescription products:
Expect requirements such as:
Many jurisdictions restrict refills for controlled substances. Colombia may similarly require either:
Compliance note: If repeats are permitted, pharmacies should expect tighter recordkeeping and more frequent reconciliation against inventory.
Your research note highlighted patient-registry requirements. Even if Colombia does not implement a single “national registry card,” the draft decree’s logic points to patient-level traceability similar to controlled-medicine norms.
Expect pharmacies to maintain, for each dispense event:
Because this involves medical treatment data, pharmacies and operators should plan for:
Business takeaway: If you are supplying pharmacies, expect them to request batch documentation, certificates of analysis, and standardized product identifiers to support reconciliation and inspections.
Dispensing flower in a pharmacy setting typically introduces requirements beyond “ordinary” OTC-style retail.
Pharmacies should anticipate:
Pharmacist obligations frequently include:
In practice, operators should plan training modules and scripts to ensure consistent counseling and to reduce regulatory risk.
The draft decree’s focus on point-of-sale identity checks is consistent with a controlled medicine distribution model.
At minimum, pharmacies should expect to:
Pharmacies should plan written procedures for:
Compliance takeaway: These refusal protocols are not only a safety measure; they are also a defensible audit artifact during inspections.
A recurring source of confusion in Colombia is the boundary between:
If the decree authorizes flower dispensation broadly, the market could evolve along two parallel routes:
Monitor whether the final decree:
Start with INVIMA’s official guidance and publications: https://www.invima.gov.co/
Your brief asks specifically about advertising or display restrictions. Even without flower-specific language, Colombia’s general approach to prescription medicine advertising typically implies stronger limits than consumer goods.
Expect rules such as:
Companies should assume that regulators will scrutinize:
Compliance takeaway: Build a conservative marketing review process now. Align content to “informational, professional, and prescription-based” messaging with internal approvals.
A key operational issue is how the decree will treat smoking and vaping.
Even where flower is legal for medical use, regulators often:
Pharmacies and manufacturers should plan for:
If the final decree contains route-of-administration constraints, it may also impact product presentation (for example, limits on accessories or any implication of recreational use).
Your notes anticipate an implementation window of Q4 2025/Q1 2026. That is plausible for a draft decree released in late July 2025, but the final timing depends on:
Businesses should watch for:
Action item: Set up regulatory monitoring for Ministry of Health publications and INVIMA communications so you don’t miss the final text or implementation guidance.
Pharmacy availability does not automatically equal affordability. Colombia’s pricing and coverage dynamics may be shaped by:
In an early rollout period, anticipate:
Business implication: Producers should model demand with conservative coverage assumptions at launch, while building evidence and documentation to support broader reimbursement discussions.
Colombia has been known for export ambition—GMP-aligned facilities and international supply strategies. A pharmacy-dispensed flower channel could materially change what “success” looks like domestically.
To sell into pharmacies, producers may need:
Export markets can tolerate longer lead times; pharmacies require:
Investor takeaway: Domestic pharmacy rollout favors operators with mature quality systems, strong documentation, and the ability to support pharmacovigilance-like workflows.
When a product moves into pharmacies, enforcement typically concentrates on:
Businesses should expect inspections to focus on whether the pharmacy can prove:
Draft decrees can evolve quickly, and operational details—prescription format, recordkeeping fields, warning language, and enforcement priorities—often arrive through follow-on guidance.
For ongoing monitoring and practical compliance support, use https://www.cannabisregulations.ai/ to track licensing and policy updates, map requirements into SOPs, and keep your team aligned as Colombia’s pharmacy-dispensing rollout develops.